In a recent I-BFM-AML collaborative study, the role of PCR-MRD collected within 5 weeks prior to HSCT was evaluated in 108 pediatric AML patients harboring one of the main recurrent AML gene rearrangements (t(8;21)(q22;q22); RUNX1-RUNX1T1, inv(16)(p13.1q22)/t(16;16)(p13.1;q22); CBFB-MYH11, t(9;11)(p22;q23); KMT2A-MLLT3 or FLT3-ITD). Here, FLT3 is linked to acute myeloid leukemia.